SAN FRANCISCO, Sept. 26, 2011 /CNW/ - Biosign Technologies Inc. (TSXV:
BIO) a medical device company focused on non-invasive, cloud-based
vital health monitoring, will be offering a free non-invasive glucose
testing demonstration during the Health 2.0 conference being held in
San Francisco today and tomorrow.
"We are providing the opportunity for anyone attending Health 2.0 to
take their own readings at a special station we setup for this purpose,
although the device is not yet approved by the FDA for sale in the
U.S.," said Dr. Scott Jenkins, CEO of Biosign Technologies. "Allowing
people to see our UFIT® medical device work for themselves is the first
step to getting this breakthrough technology into the hands of
UFIT® combines the power of the cloud for validation and analysis with
an easy to use wrist cuff for the pain-free non-invasive measurement of
vital health information. Measuring both blood glucose and blood
pressure from a single device makes this application unique. Biosign
offers additional data analysis through our Cloud DxTM platform.
Dr. Scott Jenkins, CEO of BioSign stated "Our New Cloud DxTM solution and non-invasive blood glucose data integrated with HealthSaaS
Connected Outcomes Framework® services is a significant step forward to
facilitating seamless collaboration and providing quality metrics for
the healthcare ecosystem. By working together, we plan to lower the
costs for payers and at the same time improve the quality of life for
patients with diabetes, hypertension, and cardio-vascular diseases."
About Cloud DxTM
The Cloud DxTM brand is a trademark of Biosign Technologies Inc. and is the brand
under which Biosign shall deliver services to consumers, healthcare
professionals and payers. Biosign collects data from proprietary
non-invasive devices, uses the cloud for validation, analysis and
synthesis of the data, and then makes the information available to
patients and their Circle of CareTM. We believe Cloud DxTM is the future of remote healthcare monitoring and quality patient care.
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems
through its Cloud DxTM branded solution. Cloud DxTM applications include intelligent systems for non-invasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. Biosign technology combines measurement, analysis, and
tools for disease and patient management to support global vital health
monitoring. The UFIT® medical device delivers quality data collection
and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For
more information visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign/Cloud Dx Contact: